Navigation Links
Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
Date:9/3/2009

SAN DIEGO, Sept. 3 /PRNewswire/ -- Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the Thomas Weisel Partners Healthcare Conference. The presentation is scheduled for 8:35 a.m. EDT on Wednesday, September 9, 2009, at The Four Seasons Hotel in Boston.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
2. Amira Pharmaceuticals Appoints First Vice President of Development
3. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
4. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
5. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
6. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
7. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
8. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
9. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013 According to a May 14, ... More Options for Breast Cancer Surgery,” modern medical technology has ... approach this disease in a whole new light. Since the ... now face breast cancer and mastectomies with greater ... “Before the introduction of plastic surgery to oncology, women had ...
(Date:5/22/2013)... next two decades, the cost of treating strokes in ... topping more than $180 billion a year, according to ... an aging population. The report, from the American Heart ... May 22 in the journal Stroke . ... Bruce Ovbiagele, chairman of the department of neurology at ...
(Date:5/22/2013)... 22, 2013 Recent tragedies including ... the school shooting in Newtown, Connecticut all resulted ... , Emergency medical practitioners train to respond ... Emergency Medical Services for Children (EMSC) Program specifically ... for the youngest patients. It is estimated 30 ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 HR Strategies ... hosted at the Gwinnett County Fairgrounds, on Friday May ... before, they far surpassed expectations; raising over $6,300 for ... sponsor for the event, donating the first $3,000 for ... , challenged the internal staff to match the company’s ...
(Date:5/22/2013)... Alan Mozes HealthDay Reporter , , WEDNESDAY, May ... number of American children who die each year awaiting ... research reveals. And increasing numbers of children are receiving ... of potential organ donors expanded to include not just ... a "circulatory determination of death." But it,s unclear ...
Breaking Medicine News(10 mins):Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 2Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 3Health News:More Kids Getting Donor Organs, But Gaps Persist, Study Finds 4
... SALT LAKE CITY, Jan. 5 Health-conscious consumers who ... day now have a smaller,more powerful alternative to fish ... MegaRed delivers essential omega-3 fatty acids combined with,powerful antioxidants, ... supporting,heart health. One MegaRed softgel per day -- which ...
... VIEW, Calif., Jan. 5 Based on its ... Sullivan recognizes Toshiba,America Medical Systems with the 2008 ... The company has launched a variety of,cardiovascular imaging ... cardiac ultrasound line. This product has taken,echocardiography a ...
... Treat Diseases (HTDS) www.htdsmedical.com Further to the ... company addressed several targeted merger candidates, the company is ... negotiations with Slavica Bio Chem, www.slavicabiochem.com (Slavica). ... Renuyu Biochem, a USA and a UK company, founded ...
... IRVING, Texas, Jan. 5 RBC Life Sciences ... has elected current president, John W. Price, to CEO ... is currently CEO, will remain as chairman of the ... RBC Life Sciences, a global provider of proprietary nutritional ...
... Licenses PDL,s Queen et al. Patents for Soliris(R) INCLINE VILLAGE, ... (Nasdaq: PDLI ) and Alexion Pharmaceuticals, Inc. ... the companies have entered into a definitive license agreement and ... to Alexion,s humanized antibody, Soliris(R) (eculizumab) and PDL,s patents known ...
... Jan. 5 The Ensign Group, Inc. (Nasdaq: ... has acquired Southland Healthcare Center, a 150-bed skilled ... effective January 1, 2009. The facility has been ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )"This is a strategic acquisition, and ...
Cached Medicine News:Health News:Three Times More Powerful Than Fish Oil, MegaRed(TM) Omega-3 Krill Oil Now Available Nationwide 2Health News:Three Times More Powerful Than Fish Oil, MegaRed(TM) Omega-3 Krill Oil Now Available Nationwide 3Health News:Frost & Sullivan Awards Toshiba America Medical Systems for Innovation in Cardiovascular Imaging Products and Services 2Health News:Frost & Sullivan Awards Toshiba America Medical Systems for Innovation in Cardiovascular Imaging Products and Services 3Health News:Frost & Sullivan Awards Toshiba America Medical Systems for Innovation in Cardiovascular Imaging Products and Services 4Health News:Hard To Treat Diseases (HTDS) Completes E Europe Merger 2Health News:RBC Life Sciences Promotes Industry Veteran John W. Price to CEO; Company Founder, Clinton Howard, Will Remain Chairman of the Board 2Health News:RBC Life Sciences Promotes Industry Veteran John W. Price to CEO; Company Founder, Clinton Howard, Will Remain Chairman of the Board 3Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 2Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 3Health News:The Ensign Group Acquires Texas Skilled Nursing Facility 2
(Date:5/22/2013)... May 22, 2013 Ranbaxy Laboratories Limited ... Ltd. (hereafter, Daiichi Sankyo), announced on May 22 ... years to address past conduct under prior management ... Daiichi Sankyo continues to support Ranbaxy in ... of the past which led to the investigations ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
(Date:5/22/2013)... Israel , May 22, 2013 /PRNewswire/ ... leading developer and provider of microRNA-based molecular diagnostics, announces ... and Chief Executive Officer of Rosetta Genomics, will deliver ... taking place from June 3-6, 2013 in New York ... June 4 th at 2:00 p.m. Eastern time. ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
Medicine Products: